Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30109148 | 1.00 | RIPK1 (0.42) | RIPK1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL31269590 | 0.88 | CYP3A4 (0.40) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL31269567 | 0.88 | LOXL2 (0.45) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL30109275 | 0.88 | LOXL2 (0.45) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL30109188 | 0.87 | MAPT (0.47) | RIPK1MAPTGPR88ATMCTSS | |
| SCHEMBL21715575 | 0.87 | CYP4A11 (0.46) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL2793090 | 0.86 | CYP2D6 (0.44) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL2791088 | 0.86 | ATM (0.41) | CYP3A4CYP2C9TSHRCYP2C19MAPT | |
| SCHEMBL5151480 | 0.86 | ATM (0.46) | TSHRMAPTATMCTSSCTSK | |
| SCHEMBL15875951 | 0.86 | ALDH1A1 (0.47) | RIPK1TSHRCYP2C19MAPTGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240360103-A1 | COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2024-10-31 | — | — | US | disclosed |
| WO-2023278698-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | RIPK1 1730/4885CYP3A4 2268/4885CYP2C9 3223/4885 |
| US-20240360103-A1 | COMPLEMENT INHIBITION | C5, C9, C1QBP | RIPK1 4348/4885CYP3A4 4017/4885CYP2C9 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.